Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO

share with twitter share with LinkedIn share with facebook
share via e-mail
05/25/2018 | 06:36pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the first positive Phase 1 clinical data assessing cemiplimab as a potential treatment for advanced non-small cell lung cancer (NSCLC) will be shared at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Cemiplimab is an investigational human monoclonal antibody targeting the immune checkpoint PD-1 (programmed cell death protein 1) (see also Regeneron Pharmaceuticals Inc.).

As published online in advance of ASCO, interim results from the Phase 1 dose-escalation phase and expansion cohort of patients with advanced NSCLC showed that cemiplimab monotherapy resulted in an overall response rate (ORR) of 29 percent (six of 21 patients, all of which were partial responses or non-complete responses or non-progressive disease) and a disease control rate of 57 percent (12 of 21 patients, including ORR and six stable disease or non-complete responses or non-progressive disease) as of the data cut-off date. The duration of response exceeded eight months in five of six patients. In the trial, patients received either a 1 mg/kg dose (one patient) or 200 mg flat dose (20 patients) of cemiplimab, each given every two weeks. The most common treatment-related adverse events were asthenia, pneumonitis and rash (three patients each, 14 percent).

The NSCLC expansion cohort enrolled patients whose disease had worsened after initial improvement (relapsed) or not responded (refractory) after at least one course of chemotherapy. NSCLC patients in the Phase 1 trial had failed, on average, 2.14 previous chemotherapy regimens.

"Cemiplimab is the foundation of our broader immuno-oncology program, and the clinical profile we've seen to date has encouraged us to explore the potential of this anti-PD-1 in multiple malignancies," said Israel Lowy, M.D., Ph.D., Vice President of Global Clinical Development and Head of Translational Science and Clinical Oncology, Regeneron. "In NSCLC, there remains a high unmet need despite recent advances. The positive Phase 1 results in advanced NSCLC support our strategy to advance cemiplimab in multiple Phase 3 trials exploring a number of treatment settings for this disease."

Cemiplimab being investigated in patients with NSCLC in different settings

The Regeneron and Sanofi clinical development program in NSCLC encompasses several Phase 2 and 3 trials investigating cemiplimab treatment of tumors with different PD-L1 (programmed death-ligand 1) expression levels and as a monotherapy or part of doublet or triplet combinations in the first- and second-line treatment settings. This includes a Phase 3 NSCLC trial investigating cemiplimab combination therapy versus pembrolizumab in certain first-line patients.

"The cemiplimab development program is an example of our ability to rapidly translate scientific innovation into potential treatment breakthroughs in oncology," added Joanne Lager, M.D., Head of Oncology Development, Sanofi. "The data shared at ASCO will provide an important foundation for evaluating cemiplimab in new combination regimens, with the goal of helping patients who may not benefit from existing therapies."

Additional results for cemiplimab will also be presented at ASCO

In addition to the Phase 1 advanced NSCLC data, updated results from pivotal clinical trials investigating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC) will be presented at ASCO. Additional accepted abstracts include an assessment of treatment patterns and costs in CSCC as well as overviews of clinical trials in progress for cemiplimab in cervical cancer and for REGN3767, an investigational human monoclonal antibody targeting the immune checkpoint LAG-3 (lymphocyte-activation gene 3), as either a monotherapy or in combination with cemiplimab in solid tumors and lymphoma.

Cemiplimab is currently being reviewed by the U.S. Food and Drug Administration and European Medicines Agency as a potential new treatment for patients with metastatic CSCC or patients with locally advanced CSCC who are not candidates for surgery. In addition to CSCC and NSCLC, cemiplimab is also being investigated in potentially pivotal/pivotal trials as a monotherapy for basal cell carcinoma and cervical cancer alongside exploratory trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin lymphoma and non-Hodgkin lymphoma.

Cemiplimab and REGN3767 are being jointly developed by Regeneron and Sanofi under a global collaboration agreement and were invented by Regeneron using the company's proprietary VelocImmune® technology that yields optimized fully-human antibodies.

Cemiplimab and REGN3767 are currently under clinical development, and their safety and efficacy have not been fully evaluated by any regulatory authority.

Keywords for this news article include: Regeneron Pharmaceuticals Inc, Business, Lymphoma, Oncology, Carcinomas, Hematology, Lung Neoplasms, Clinical Research, Health and Medicine, Non-Small Cell Lung Cancer, Biopharmaceutical Companies, Clinical Trials and Studies, Immunoproliferative Disorders, Lymphoproliferative Disorders, Lymphatic Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
05/25REGENERON PHARMACEUTICALS : and Sanofi Share First Positive Clinical Data for Ce..
05/25SANOFI : Investigators from Sanofi Pasteur Target Whooping Cough (Humoral immuni..
05/25SANOFI : P946 million from Sanofi set aside for Dengvaxia recipients
05/25SANOFI : DOJ summons Duque, Garin to Dengvaxia probe on June 25
05/24ALLERGY MEDICINE MARKET SCENARIO FOC : The global Allergy Medicine market Resear..
05/24SANOFI : Swansea University Medical School chosen to host diabetes centre of exc..
05/24SANOFI : Amgens Repatha gets EU cardio risk reduction label
05/24SANOFI : and Swansea collaborate on UK`s first diabetes centre of excellence
05/23Why the world needs more than one Ebola vaccine
05/23SANOFI : FDA to review Zynquista (sotagliflozin) as potential treatment for type..
More news
News from SeekingAlpha
05/25Xeris Pharmaceuticals on deck for IPO 
05/24'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisou.. 
05/24TOP WALL STREET HEALTHCARE GAINERS F : Allergan, CVS Health, Patterson, Sanofi, .. 
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
05/23NOVAVAX : All Eyes On Q1 2019 
Financials (€)
Sales 2018 35 175 M
EBIT 2018 8 585 M
Net income 2018 5 100 M
Debt 2018 15 003 M
Yield 2018 4,69%
P/E ratio 2018 15,84
P/E ratio 2019 14,85
EV / Sales 2018 2,76x
EV / Sales 2019 2,59x
Capitalization 82 158 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 77,0 €
Spread / Average Target 17%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-8.45%95 715
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708